Literature DB >> 18669508

Nerve function and dysfunction in acute intermittent porphyria.

Cindy S-Y Lin1, Arun V Krishnan, Ming-Jen Lee, Alessandro S Zagami, Hui-Ling You, Chih-Chao Yang, Hugh Bostock, Matthew C Kiernan.   

Abstract

Acute intermittent porphyria (AIP) is a rare metabolic disorder characterized by mutations of the porphobilinogen deaminase gene. Clinical manifestations of AIP are caused by the neurotoxic effects of increased porphyrin precursors, although the underlying pathophysiology of porphyric neuropathy remains unclear. To further investigate the neurotoxic effect of porphyrins, excitability measurements (stimulus-response, threshold electrotonus, current-threshold relationship and recovery cycle) of peripheral motor axons were undertaken in 20 AIP subjects combined with the results of genetic screening, biochemical and conventional nerve conduction studies. Compared with controls, excitability measurements from five latent AIP patients were normal, while 13 patients who experienced acute porphyric episodes without clinical neuropathy (AIPWN) showed clear differences in their responses to hyperpolarizing currents (e.g. reduced hyperpolarizing I/V slope, P < 0.01). Subsequent mathematical simulation using a model of human axons indicated that this change could be modelled by a reduction in the hyperpolarization-activated, cyclic nucleotide-dependent current (I(H)). In contrast, in one patient tested during an acute neuropathic episode, axons of high threshold with reduced superexcitability, consistent with membrane depolarization and reminiscent of ischemic changes. It is proposed that porphyrin neurotoxicity causes a subclinical reduction in I(H) in AIPWN axons, whereas porphyric neuropathy may develop when reduced activity of the Na(+)/K(+) pump results in membrane depolarization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669508     DOI: 10.1093/brain/awn152

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

1.  The voltage dependence of I(h) in human myelinated axons.

Authors:  James Howells; Louise Trevillion; Hugh Bostock; David Burke
Journal:  J Physiol       Date:  2012-02-06       Impact factor: 5.182

2.  Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.

Authors:  Carmen Unzu; Ana Sampedro; Itsaso Mauleón; Manuel Alegre; Stuart G Beattie; Rafael Enríquez de Salamanca; Jolanda Snapper; Jaap Twisk; Harald Petry; Gloria González-Aseguinolaza; Julio Artieda; María Sol Rodríguez-Pena; Jesús Prieto; Antonio Fontanellas
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

3.  Ih contributes to increased motoneuron excitability in restless legs syndrome.

Authors:  Dirk Czesnik; James Howells; Michael Bartl; Elisabeth Veiz; Rebecca Ketzler; Olga Kemmet; Arthur S Walters; Claudia Trenkwalder; David Burke; Walter Paulus
Journal:  J Physiol       Date:  2018-11-24       Impact factor: 5.182

4.  Peripheral neuropathy due to dinitrophenol used for weight loss: something old, something new.

Authors:  Lauren Phillips; Mike A Singer
Journal:  Neurology       Date:  2013-01-30       Impact factor: 9.910

5.  Hyperpolarization-activated cyclic-nucleotide-gated channels potentially modulate axonal excitability at different thresholds.

Authors:  Dinushi Weerasinghe; Parvathi Menon; Steve Vucic
Journal:  J Neurophysiol       Date:  2017-09-13       Impact factor: 2.714

6.  Excitability and the safety margin in human axons during hyperthermia.

Authors:  James Howells; Dirk Czesnik; Louise Trevillion; David Burke
Journal:  J Physiol       Date:  2013-04-22       Impact factor: 5.182

7.  Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability.

Authors:  Michelle A Farrar; Susanna B Park; Cindy S-Y Lin; Matthew C Kiernan
Journal:  J Physiol       Date:  2012-09-24       Impact factor: 5.182

Review 8.  Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.

Authors:  Mohamed Kazamel; Robert J Desnick; John G Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-07       Impact factor: 5.081

9.  Paediatric porphyria and human hemin: a treatment challenge in a lower middle income country.

Authors:  Syeda Anum Fatima; Humaira Jurair; Qalab Abbas; Arshalooz Jamila Rehman
Journal:  BMJ Case Rep       Date:  2020-01-08

10.  Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease.

Authors:  Ria Arnold; Bruce A Pussell; Timothy J Pianta; Virginija Grinius; Cindy S-Y Lin; Matthew C Kiernan; James Howells; Meg J Jardine; Arun V Krishnan
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.